Priti Patel

Priti Patel serves as the Interim Consultant Chief Medical Officer (CMO) at AsherBio, where she oversees the clinical development organization and clinical trials. She has a proven track record in the biotechnology and pharmaceutical industry, particularly in oncology, having held significant roles in both large and small companies globally. Patel has successfully developed, evaluated, and advanced numerous cancer therapeutics. Previously, she was the Chief Medical Officer at Neoelukin Therapeutics, responsible for the clinical development of NL-201, a novel protein therapy for cancer. She also held the position of Vice President, Head of Hematology Clinical Development at AstraZeneca, and was a Senior Medical Director at Acerta Pharma before its acquisition by AstraZeneca. During her tenure, she led the clinical strategy and trials for blood cancer therapeutics, including overseeing over six Phase 3 and twenty Phase 1/2 studies for acalabrutinib, resulting in its global approval for chronic lymphocytic leukemia and mantle cell lymphoma. Patel also contributed to the development and approval of carfilzomib for multiple myeloma at Onyx Pharmaceuticals. She has co-authored numerous scientific papers and holds a B.A. and Masters in Public Health from Johns Hopkins University, an M.D. from the University of Vermont College of Medicine, and completed her medical training in internal medicine, hematology, and medical oncology at Stanford University Hospital.